Trial Profile

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of RBI-4000 in Healthy Volunteers

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 25 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RBI-4000 (Primary)
Indications Rabies
Focus Adverse reactions; First in man; Pharmacodynamics
Sponsors Replicate Bioscience

Most Recent Events

07 Feb 2025 According to Replicate Bioscience Media Release, company announced that data from this study have been published in Nature Communications.
02 Aug 2024 According to ClinicalTrials.gov record , this trial was terminated due to Strategic business decision (not related to safety, efficacy, or quality)
02 Aug 2024 Status changed from active, no longer recruiting to discontinued.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com